Phio Pharmaceuticals Corp.: insider trades · United States · SEC (Form 4)

About Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp. is a U.S.-listed biotechnology company trading on the NASDAQ market in the United States. It is focused on immuno-oncology drug discovery and development, built around its proprietary INTASYL™ platform, a self-delivering RNA interference technology designed to modulate disease-relevant gene expression without relying on conventional delivery systems. From an investor’s perspective, Phio remains a development-stage micro-cap biotech: it has no approved commercial product, limited operating history, and a valuation that is highly sensitive to clinical progress, intellectual property protection, and access to capital. The company’s history traces back to Cutanea Life Sciences, which was founded by CEO Robert Bitterman; Phio later adopted its current name to reflect a strategic pivot toward cancer immunotherapy. According to its SEC filings, the company relocated its corporate headquarters from Marlborough, Massachusetts to King of Prussia, Pennsylvania, while maintaining a small laboratory presence in Worcester, Massachusetts. That move, together with broader cost rationalization efforts, underscores a lean operating model typical of early-stage biopharma companies. Phio’s core business is concentrated on advancing product candidates derived from INTASYL. The company identifies PH-762 as its lead development compound and also references PH-894 as part of its pipeline. In preclinical work, INTASYL has been evaluated against multiple immune-oncology targets, including PD-1, BRD4, CTLA-4, TIGIT and CTGF. The company also emphasizes a sizeable patent estate for a company of its scale, with issued patents and patent families covering the INTASYL platform and related therapeutic uses. However, Phio is still reliant on third-party manufacturers for drug substance and clinical supply production. In competitive terms, Phio operates in a crowded and rapidly evolving immuno-oncology field dominated by much larger pharmaceutical groups, venture-backed biotech peers, academic research institutions and other public and private developers. Its potential differentiation lies in the ease of incorporating INTASYL into existing cell-therapy workflows and in the platform’s self-delivering design. At the same time, the company faces the classic risks of an early clinical biotech: uncertain efficacy, safety and manufacturability, as well as a strong likelihood of future financing needs. A key recent development was disclosed in Phio’s Form 10-Q for the quarter ended September 30, 2025. In July 2025, the company entered into a comprehensive drug substance development services agreement with a U.S. manufacturing partner to support analytical, process-development and cGMP manufacturing work for PH-762. This followed the termination of its clinical co-development arrangement with AgonOx and the wind-down of the associated Phase 1 study. For investors in France, Belgium or Switzerland, Phio is best viewed as a high-risk NASDAQ-listed healthcare story driven by platform validation, pipeline execution and financing discipline rather than near-term revenues.